Hjem › B-celle lymfom › Ohio
B-celle lymfom kliniske forsøg i Ohio
17 studier for B-celle lymfom søger deltagere på steder i Ohio.
Byer i Ohio
Officiel studietekst (engelsk)
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
- University Hospitals Seidman Cancer Center, Cleveland
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT06343311Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Cincinnati Children's Hospital Medical Center, Cincinnati
RekruttererObservationsstudie
Alder 0 til 38 · Alle køn · Opdateret 1. okt. 2026 · NCT06131801A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- University Hospitals, Cleveland
- Cleveland Clinic Foundation, Cleveland
- Ohio State University Comprehensive Cancer Center, Columbus
- og 1 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT06742996Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
- Ohio State University Medical Center Dept. of Internal Medicine, Division of Hematology, Columbus
RekruttererFase 2
Alder 60 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06052826A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Cleveland Clinic, Cleveland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07101328Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Research Site, Columbus
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 11. sep. 2026 · NCT06526793Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
- Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center, Cleveland
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2026 · NCT07225439A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Research Site, Columbus
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 8. sep. 2026 · NCT06564038A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
- Clinical Trial Site, Cleveland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 4. sep. 2026 · NCT06393738Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- University of Cincinnati (UC) Physicians Company, LLC, Cincinnati
- Cleveland Clinic, Cleveland
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 25. aug. 2026 · NCT05826535A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
- University of Cincinnatti Medical Center, Cincinnatti
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 17. aug. 2026 · NCT06528301A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Oncology Hematology Care Clinical Trials, Cincinnati
- University of Cincinnati, Cincinnati
- Cleveland Clinical Taussig Cancer Center, Cleveland
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 4. aug. 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- The Ohio State University Wexner Medical Center James Cancer, Columbus
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 13. jul. 2026 · NCT04792489A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma
- Ohio State University Comprehensive Cancer Center, Columbus
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 27. maj 2026 · NCT07609030The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Gabrail Cancer Center Research,, Canton
RekruttererFase 1/2
Alder 12 til 95 · Alle køn · Opdateret 15. apr. 2026 · NCT04329728Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies, Cleveland
- Nationwide Children's Hospital, Columbus
RekruttererFase 1
Alder 1 til 21 · Alle køn · Opdateret 6. dec. 2024 · NCT05476770Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma
- University Hospitals Seidman Cancer Center, Cleveland
- Taussig Cancer Institute | Cleveland Clinic, Cleveland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 21. okt. 2024 · NCT05312801Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.